Maasoumy, Benjamin, Geretti, Anna Maria ORCID: 0000-0002-3670-6588, Frontzek, Andre, Austin, Harrison, Aretzweiler, Gudrun, Garcia-Alvarez, Monica, Leuchter, Susanne, Simon, Christian O, Marins, Ed G, Canchola, Jesse A et al (show 3 more authors)
(2020)
HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination.
HEPATOLOGY COMMUNICATIONS, 4 (7).
pp. 983-997.
This is the latest version of this item.
Text
HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination.pdf - Published version Download (716kB) | Preview |
|
Text
BM_rev_finalv2_HBV RNA_Main paper 20200311.docx - Author Accepted Manuscript Download (62kB) |
Abstract
Despite effective hepatitis B virus (HBV)-DNA suppression, HBV RNA can circulate in patients receiving nucleoside/nucleotide analogues (NAs). Current assays quantify HBV DNA by either real-time polymerase chain reaction (PCR), which uses DNA polymerase, or transcription-mediated amplification, which uses reverse-transcriptase (RT) and RNA polymerase. We assessed the effect of RT capability on HBV-DNA quantification in samples from three cohorts, including patients with quantified HBV RNA. We compared the HBV-DNA levels by real-time PCR (cobas HBV, Roche 6800/8800; Xpert HBV, Cepheid), transcription-mediated amplification (Aptima HBV, Hologic), and real-time PCR with added RT capability (cobas HBV+RT). In the first cohort (n = 45) followed over 192 weeks of NA therapy, on-treatment HBV-DNA levels were higher with cobas HBV+RT than cobas HBV (mean difference: 0.14 log<sub>10</sub> IU/mL). In a second cohort (n = 50) followed over 96 weeks of NA therapy, HBV-DNA viral load was significantly higher with the cobas HBV+RT and Aptima HBV compared with the cobas HBV test at all time points after initiation of NA therapy (mean difference: 0.65-1.16 log<sub>10</sub> IU/mL). A clinically significant difference was not detected between the assays at baseline. In a third cohort (n = 53), after a median of 2.2 years of NA therapy, we detected HBV RNA (median 5.6 log<sub>10</sub> copies/mL) in 23 patients (43.4%). Median HBV-DNA levels by Aptima HBV were 2.4 versus less than 1 log<sub>10</sub> IU/mL in samples with HBV RNA and without HBV RNA, respectively (<i>P</i> = 0.0006). In treated patients with HBV RNA, Aptima HBV measured higher HBV-DNA levels than Xpert HBV and cobas HBV. <i>Conclusion:</i> Tests including an RT step may overestimate HBV DNA, particularly in samples with low viral loads as a result of NA therapy. This overestimation is likely due to amplification of HBV RNA and may have an impact on clinical decisions.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | Liver Disease, Digestive Diseases, Infectious Diseases, Hepatitis - B, HIV/AIDS, Hepatitis, Genetics, Infection, 3 Good Health and Well Being |
Depositing User: | Symplectic Admin |
Date Deposited: | 06 Aug 2020 07:17 |
Last Modified: | 17 Mar 2024 09:04 |
DOI: | 10.1002/hep4.1520 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3096515 |
Available Versions of this Item
-
HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination. (deposited 05 Aug 2020 08:59)
- HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination. (deposited 06 Aug 2020 07:17) [Currently Displayed]